Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Merck & Co. (NYSE:MRK) and Gilead Sciences Inc. (NYSE:GILD) are two pharmaceutical heavyweights whose stocks tell very ...

Defendant Yisel Lopez has been found in contempt for violating an asset freeze order through the sale of property.

Roche executive Daniel O’Day is to take the helm at Gilead after John Milligan steps down as CEO at the end of this year, the company has announced. Currently CEO of Roche Pharmaceuticals since ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule ...

Gilead will pay Genesis $35 million for three targets. There could also be further payments if more targets are identified, along with milestone payments. Genesis previously collaborated with ...

Yuhan and Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, ended a research project after securing ...

Mohit Bansal has given his Hold rating due to a combination of factors including Gilead Sciences’ current position and future prospects within the pharmaceutical market. The optimism surrounding ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...